药物评价：BAL-8557——一种新型广谱三唑类抗真菌药。
Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.
作者信息
Odds Frank C
机构信息
Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK.
出版信息
Curr Opin Investig Drugs. 2006 Aug;7(8):766-72.
PMID:16955689
Abstract
Basilea Pharmaceutica is developing BAL-8557, a water-soluble prodrug of the triazole BAL-4815, for the potential treatment of fungal infections. By August 2005, a phase II study in oral candidiasis was underway. In September 2005, phase III trials were planned for invasive Candida and mold infections, including aspergillus and zygomycetes.
摘要
巴塞利亚制药公司正在研发BAL-8557，它是三唑类药物BAL-4815的水溶性前体药物，用于潜在治疗真菌感染。截至2005年8月，一项针对口腔念珠菌病的II期研究正在进行中。2005年9月，计划针对侵袭性念珠菌和霉菌感染开展III期试验，包括曲霉菌和接合菌。
Zotero 插件